On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Inge Marie Svane

ResearcherPublications, citations & collaboration network

Inge Marie Svane is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Inge Marie Svane have?

ScholarIQindexed works

Inge Marie Svane has 817 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Inge Marie Svane have?

ScholarIQcitation count

Inge Marie Svane has 24,070 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Inge Marie Svane?

ScholarIQh-index

Inge Marie Svane has an h-index of 72 in OpenAlex.

What is the i10-index of Inge Marie Svane?

ScholarIQi10-index

Inge Marie Svane has an i10-index of 273 in OpenAlex.

What is the ORCID of Inge Marie Svane?

ScholarIQorcid

The ORCID for Inge Marie Svane is on the source record.

What is the OpenAlex record for Inge Marie Svane?

ScholarIQopenalex

The OpenAlex for Inge Marie Svane is on the source record.

What are the most-cited papers on Inge Marie Svane?

ScholarIQmost cited works
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
The Lancet Oncology. 20152,674 Citations
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia M. Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, I.M. Noringriis, Tine J. Monberg, Rikke Boedker Holmstroem, Lidwina D.V. Wever, M. van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, A. Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A. M. Stevense‐den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan‐Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers‐Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebæk, Lisbet Rosenkrantz Hölmich, Alexander C. J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, A. Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen
New England Journal of Medicine. 2022558 CitationsOPEN ACCESS
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci
The Lancet Oncology. 2021392 CitationsOPEN ACCESS
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, Eva Ellebæk, Marco Donia, Rikke Boedker Holmstroem, Tobias Wirenfeldt Klausen, Cecilie Oelvang Madsen, Shamaila Munir Ahmed, Stine Emilie Weis-Banke, Morten Orebo Holmström, Helle Westergren Hendel, E. Ehrnrooth, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen, Inge Marie Svane
Nature Medicine. 2021213 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account